ABSTRACT
In long-term follow-up studies of subthalamic nucleus deep brain stimulation (STN-DBS), the maintained control of many Parkinson disease (PD) symptoms contrasts with a progressive increase in gait dysfunction (and notably the appearance of freezing episodes) in approximately 5% to 20% of the patient population. This becomes a major cause of disability and dependence [1] [2] [3] [4] [5] [6] [7] (table e-1 on the Neurology ® Web site at www.neurology.org). However, we do not know whether the axial symptoms that seem to predominate after several years of successful DBS are signs of the progression of nondopaminergic degenerative PD lesions 8 or whether they emerge simply because they are less sensitive to the commonly used stimulation settings. Optimal control of segmental parkinsonian signs is initially obtained at an STN stimulation frequency of 130 Hz (and potentially up to 185 Hz) in patients who are free of severe gait disorders, with a typical worsening of motor symptoms with STN-DBS Յ 30 Hz. 9, 10 These observations prompted us to wonder whether gait disorders could be managed by using other combinations of STN-DBS parameters. First, the stimulation voltage seems to be the most critical parameter in STN-DBS, followed by the frequency 9 ; one logical option would be to modify these settings to control parkinsonian symptoms.
Second, recent data on the stimulation of structures near the STN (part of the mesencephalic locomotor area [MLA] and the pedunculopontine nucleus [PPN] ) evidenced an improvement in gait disorders in PD. [11] [12] [13] The stimulation frequency range used was lower than for the STN area (from 10 -25 Hz 11, 12 up to 70 Hz 14 ) . Given the anatomic proximity of the STN and the PPN (just 5 mm), one could imagine that high STN-DBS frequencies might exert unfavorable effects on the MLA.
We investigated PD patients who developed severe gait disorders and freezing episodes after several years of STN-DBS by looking at their response to 1) an energy effect (i.e., high voltages vs the patient's usual voltage) at a frequency of 130 Hz and 2) a frequency effect (i.e., 130 Hz vs approximately half this frequency [60 Hz] but at equivalent delivered energy levels).
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METHODS Thirteen PD patients who developed severe gait disorders in the 5 years after initiation of STN-DBS gave their informed consent to participate. The patients' median age was 70 [first quartile-third quartile, Q1-Q3: 66 -72] years, and the median disease duration was 18 [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] years. None of the patients had exhibited dopa-resistant axial signs before surgery. The median time since STN-DBS initiation was 5 [4 -5] years. The preoperative L-dopa motor response on the Unified Parkinson's Disease Rating Scale (UPDRS) was 55% [45-60%]. After 1 year of STN-DBS, all patients displayed a good outcome, with a median reduction in the motor UPDRS score of 52% [48 -60%] and the disappearance of motor fluctuations. By the time of the study, the average "on" vs "off" STN-DBS reduction in UPDRS was 45% [43-55%] compared with 52% in the early postoperative period. The median L-dopa sensitivity (% UPDRS III score improvement) was 45% at the time of the study. The L-dopa median daily dose equivalent was 675 mg.
All patients displayed the same profile: the progressive appearance of gait disorders (notably including increased gait hypokinesia and postural instability), which were partially improved by L-dopa (median time of appearance after surgery: 2.5 [2] [3] years). Furthermore, all patients presented freezing episodes in the off-medication state. None of the patients presented a directly L-dopa-induced ("on-freezing") episode. Before the study, the STN-DBS and dopa-therapy parameters had been optimized for each patient (the median stimulation settings being 130 Hz, 3 volts [V], and 60 s).
We used a standardized, clinical, timed test for gait evaluation: the Stand-Walk-Sit (SWS) Test over a distance of 7 meters. 16 The test results-the number of freezing episodes (the primary endpoint), completion time, and the number of stepswere always assessed by the same, blinded investigator, whereas the stimulation parameters were modified by a second neurologist. Patients were evaluated under "off-drug" conditions after 12 hours of therapy withdrawal. Monopolar stimulation was performed with the contact that had given the best clinical results over the previous years: ventral contacts (0 or 1) were used in 10 patients, and dorsal contacts (2 or 3) were used in 3 patients. For each randomized condition (i.e., 60 Hz, 130 Hz, or off), the starting voltage was also randomized (either high or low). The applied voltage was then increased (or decreased) in 0.5-V steps. To specifically study the frequency effect (and not a general energy effect), we maintained the same "energy level" for stimulation at both 60 and 130 Hz by varying the voltage. For each patient, the 60-DBS conditions were equivalent to the 130-DBS conditions in terms of energy delivered (calculated according to the total electrical energy delivered (TEED) formula: TEED (1 second) ϭ voltage 2 ϫ frequency ϫ pulse width/impedance). 12 The pulse width was constant (60 s The assessment lasted approximately 4 hours in a single, morning session, to minimize circadian fluctuation. To limit the impact of stimulation after-effects, we strictly maintained an interval of 1 hour between each frequency change and 10 minutes between each voltage change. 17 The Conover nonparametric test was used to compare conditions. 18 Principal effects seen in an analysis of variance on ranks were further analyzed in contrast studies using the Bonferroni post hoc test. A significance level of 0.05 was chosen.
RESULTS First part.
In the 130-Hz/high-voltage condition, the SWS completion time and the number of steps and freezing episodes increased. The results were similar to those seen in the "off" DBS condition (table) .
In There was an effect of condition on the completion time [F(4,9) ϭ 13.8, p ϭ 0.001] and the number of steps [F(4,9) ϭ 10.5, p ϭ 0.002] and freezing episodes [F(4,9) ϭ 11.6, p ϭ 0.001]. Post hoc comparisons revealed that 60-Hz DBS at the high energy/equivalent voltage gave the best results for each parameter. Both 60-DBS conditions were better than the two 130-DBS conditions and the off-DBS condition.
In terms of the UPDRS III scores, there was no difference between 60 and 130 Hz, and all "on" conditions were better than "off" DBS [F(3,14) ϭ 8.8, p ϭ 0.002]. Compared with the off-DBS condition, there was an improvement in gait, tremor, rigidity, and akinesia in the 60-DBS and 130-DBS conditions, with no difference between the latter.
Follow-up data. After 8 months, the clinical gait benefit with the 60-Hz high energy/equivalent voltage was still satisfactory in 85% (n ϭ 11) of the patients, although it had been necessary to slightly increase the daily L-dopa dose (by approximately 200 mg/day) to achieve the same clinical benefits for segmental parkinsonian symptoms.
Two patients went back to 130 Hz, respectively 2 and 3 months later, because of a worsening of segmental symptoms, especially tremor, which was not well controlled by the slight L-dopa increase.
DISCUSSION Our results demonstrated 1) a negative effect on gait of increasing voltages at a fixed frequency of 130 Hz in PD patients with severe gait disorders after several years of STN-DBS and 2) a positive effect of reduced frequency at equivalent delivered energy levels, with the greatest benefit on freezing episodes appearing in the 60-Hz highvoltage/equivalent-energy condition.
A small, nonsignificant increase in the UPDRS motor score (which never exceeded 4 points) was observed with 60 Hz at the high energy/equivalent voltage, when compared with 130 Hz at the usual voltage. However, we saw no differences between the 60-DBS and 130-DBS conditions in terms of axial and gait subscores, probably because of the moderate clinical improvements in terms of speech, standing, and postural stability and the subscores' lower sensitivity to change. The slight reduction in akinesia for 60 Hz at the high voltage/equivalent energy (which nevertheless did not reach significance) may have contributed to the reduction in the number of freezing episodes during gait. 19 The 130-and 60-Hz conditions did not differ significantly in terms of the tremor and rigidity subscores (figure 2).
The underlying pathophysiologic mechanisms and structures involved in these effects remain to be determined. In very advanced PD, a change in STN function caused by direct high-frequency stimulation of this area (with a negative impact on gait) is one obvious possibility. Furthermore, the greater clinical impact of high voltages (more than 3 V) could also suggest current diffusion to structures around the STN electrode in general and to fibers that have lower thresholds than somata in particular. 20 Because the PPN is just 5 mm away from the STN (and its projections are even closer), high frequency STN-DBS could exert unfavorable effects on these areas. Direct, low-frequency (10-to 25-Hz) stimulation of the human PPN produces a gait improvement, whereas high frequencies (Ͼ80 Hz) produce a worsening. [11] [12] [13] Furthermore, in animals, 60-Hz stimulation of the PPN's descending projections may exert a "push" toward locomotion. 21 Further confirmatory studies are required, but our results prompt consideration of a new strategy for twostage STN-DBS frequency optimization, with 130 Hz at the usual voltage during the initial years of STN-DBS and then 60 Hz at a high energy/equivalent voltage in patients developing severe gait disorders after several years of STN-DBS. 
